Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Molecular Immunology|August 12, 2003
Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer modelK A Gelderman, J Hakulinen, M Hagenaars, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2000
Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1S Junnikkala, T S Jokiranta, M A Friese, et al.
Scandinavian Journal of Immunology|March 1, 2011
Defective central tolerance in Aire-deficient mice is not sufficient to induce symptomatic autoimmunity during lymphopenia-induced T cell proliferationE Kekäläinen, M-K Lehto, E Smeds, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole bloodJ Vuorte, P J Lindsberg, M Kaste, et al.
The Journal of Experimental Medicine|July 1, 1990
Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysisS Meri, B P Morgan, M Wing, et al.
International Journal of Cancer|June 11, 1997
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancerG A Jarvis, J Li, J Hakulinen, et al.
British Journal of Cancer|October 29, 2002
Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cellsS Junnikkala, J Hakulinen, H Jarva, et al.
Infection and Immunity|August 17, 2002
The yeast Candida albicans binds complement regulators factor H and FHL-1T Meri, A Hartmann, D Lenk, et al.
European Journal of Ophthalmology|December 1, 2007
The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degenerationS P Seitsonen, I E Jarvela, S Meri, et al.
Leukemia & Lymphoma|November 8, 2001
Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphomaA Harjunpää, T Wiklund, J Collan, et al.
Pageof 15